The quantity of data that is currently produced in everyday life and practically in every sector, is...
Director of Department of Internal Medicine and Head of General Medicine and Liver Unit, Humanitas Research Hospital
Education and Academic Background
Prof. Bruno got his degree in Medicine at the University of the Studies of Milan (1978), he went on to complete a residency degree in Internal Medicine at the University of Pavia (1983). He was the Head of the Internal Medicine and Liver Unit at AO Fatebenefratelli – Oftalmico, Milan, Italy, from 2003 to 2015. He became accredited as a full Professor of Gastroenterology at the Italian National Professorship Qualification in December 2013 (Area 06/D4, full Professor). He was Lecturer of Gastroenterology at the University of the Studies of Milan (2004-11) and of Internal Medicine at the University of Milan-Bicocca (2013-15). Prof. Bruno authored more than 250 scientific articles published by international peer-reviewed journals (Lancet, Annals of Internal Medicine, New England Journal of Medicine, Gastroenterology). He is an acknowledged opinion leader in the field epidemiology, natural history and therapy of Chronic viral hepatitis. As of April 2015, he is a Full Professor of Internal Medicine at Humanitas University, the Director of the Department of Internal Medicine and Head of General Medicine and Liver Unit at Humanitas Research Hospital.
Scientific and Research Interests
Research and Clinical Areas of Interest Area of clinical interest: anti-viral therapy of chronic hepatitis (HCV and HBV). Diagnosis and Therapy of portal hypertension and of complications of cirrhosis. Area of research interest: Natural history of chronic liver diseases of viral etiology. Predictive markers of disease progression in subjects affected by liver cirrhosis, HCC, metabolic syndrome and non-alcoholic steatohepatitis.
1: Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016 Mar 23.
2: Bruno S, Thompson AJ, Critelli R, Crosignani A, Rossi S, De Lisi S, Cariani E, Zermiani P, Vaira V, Boccaccio V, Maisonneuve P, Villa E. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study. Antiviral Res. 2015 Jan;113:27-32.
3: Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug;61(2):200-9.
4: Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012 Sep;143(3):608-18.e1-5.
5: Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195-206.